Leoung G S, Mills J, Hopewell P C, Hughes W, Wofsy C
Ann Intern Med. 1986 Jul;105(1):45-8. doi: 10.7326/0003-4819-105-1-45.
All patients with the acquired immunodeficiency syndrome and a first episode of Pneumocystis carinii pneumonia seen at the San Francisco General Hospital between November 1984 and April 1985 were evaluated for oral treatment with dapsone (100 mg/d) plus trimethoprim (20 mg/kg body weight X d). All 15 patients who met the entry criteria improved clinically and radiographically within 3 to 10 days after starting treatment. Repeat pulmonary function tests and gallium lung scans after 3 weeks of therapy also showed improvement. Although side effects occurred in 14 patients, in only 2 were they severe enough to require stopping therapy. Both of these patients had worsening skin rash, and dapsone-trimethoprim therapy was stopped after 10 days. When compared with trimethoprim-sulfamethoxazole or pentamidine used to treat P. carinii pneumonia in similar patients, oral dapsone-trimethoprim is at least as effective, seems to be better tolerated, and may have a lower frequency of serious side effects.
1984年11月至1985年4月期间，在旧金山综合医院就诊的所有获得性免疫缺陷综合征患者及初次发作卡氏肺孢子虫肺炎患者，均接受了口服氨苯砜（100毫克/天）加甲氧苄啶（20毫克/千克体重×天）治疗的评估。所有符合入选标准的15名患者在开始治疗后的3至10天内临床症状和影像学表现均有所改善。治疗3周后的重复肺功能测试和镓肺扫描也显示有所改善。虽然14名患者出现了副作用，但只有2名患者的副作用严重到需要停止治疗。这两名患者的皮疹均加重，氨苯砜 - 甲氧苄啶治疗在10天后停止。与用于治疗类似患者卡氏肺孢子虫肺炎的甲氧苄啶 - 磺胺甲恶唑或喷他脒相比，口服氨苯砜 - 甲氧苄啶至少同样有效，似乎耐受性更好，且严重副作用的发生率可能更低。
